Celgene is known as a creative yet disciplined dealmaker, so the fact that the big biotech company is investing $1bn up front under a 10-year agreement with Juno Therapeutics shows that Celgene sees a lot of value in the early-stage, closely-watched field of chimeric antigen T-cell receptor (CAR-T) therapies.
Celgene shows CAR-T confidence with $1bn Juno investment
Celgene is known as a creative yet disciplined dealmaker, so the fact that the big biotech company is investing $1bn up front under a 10-year agreement with Juno Therapeutics shows that Celgene sees a lot of value in the early-stage, closely-watched field of chimeric antigen T-cell receptor (CAR-T) therapies.
More from Anticancer
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
More from Therapy Areas
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.